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Abstract
Background: New therapeutic principles in clinical oncology require the adjustment of response criteria to
govern therapy decisions. For advanced hepatocellular carcinoma (HCC) a new era has recently begun by the
approval of the multikinase inhibitor sorafenib. As a unique feature, HCC usually develops in a diseased liver and
current imaging technologies employing classical response criteria have not been prospectively evaluated for this
new treatment.
Methods:  MRI signal patterns were assessed in 21 advanced HCC patients receiving sorafenib. MRI was
performed at baseline and in short-term intervals thereafter. Signal changes under therapy on T1WI, T2WI and
post-gadolinium images including necrosis volume and its ratio to the entire tumor volume were compared to
baseline imaging. To assess the association between the categorical variables, Fisher's exact tests were applied for
a statistical analysis. Survey time ranged from 2–65 weeks, and a total of 39 target lesions were evaluated.
Results: Signal abnormalities during sorafenib therapy were disclosed by T1WI and T2WI in 15/21 patients. The
predominant tumor signal change was hyperintensity on both T1WI and T2WI. Interestingly, most patients
developed MRI signal changes within 4 weeks of therapy; in contrast, two non-responders did not show any signal
alteration at follow-up. Under therapy, 16/21 patients presented with new or progressive necrosis, whereas 7
patients achieved temporarily >75% tumor necrosis under sorafenib. Significantly associated MRI variables were
increase in T1WI signal and tumor necrosis (p = 0.017) as well as increase of tumor necrosis with an elevated
ratio of necrotic to vital tumor areas (p = 0.002). Remarkably, some (3/13) of the patients developing necrotic
tumor areas showed a relevant (>20%) increase in tumor volume, which should be considered in the assessment
of imaging studies.
Conclusion: As sorafenib induces early intralesional necrosis with profound changes in T1WI/T2WI MRI signal
intensities and measurable necrotic tumor areas in most HCC patients, early MRI-based evaluation could pave
the way for its rationale and cost-effective application.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide, with approximately 500,000
new cases per year [1,2]. Patients with unresectable tumor
manifestations or metastatic disease exhibit median sur-
vival times of only a few months [3]. Sorafenib, which is
a novel oral multikinase inhibitor [4], presents a promis-
ing new therapeutic option for HCC, as demonstrated in
preclinical and recent clinical phase II and III studies by
Abou-Alfa et al. [5] and Llovet et al. [6], respectively. Sor-
afenib hits tumor cells on multiple levels such as the Raf/
MEK/ERK signalling pathway, as well as angiogenesis by
targeting vascular endothelial growth factor receptors-1/-
2/-3 (VEGFR-1/-2/-3) or platelet derived growth factor
receptor beta (PDGFR-β) tyrosine kinases [7-9]. Based on
the highly encouraging findings in a phase III trial [6], sor-
afenib has been approved recently for the treatment of
unresectable advanced HCC. In this context, it is of
utmost importance to define non-invasive tools, which
are suitable for monitoring and governance of this novel
therapy.
During HCC therapy, the special environment of primary
liver tumor lesions presents a unique condition that has to
be carefully taken into account when evaluating results of
diagnostic imaging procedures such as CT or MRI. Moreo-
ver, it has been questioned whether "classical" or the
recently revised Response Evaluation Criteria in Solid
Tumors (RECIST) criteria alone [10,11] are reliable for the
assessment of new molecular therapeutics [12-15].
The rationale of our MR-imaging observation study was to
identify and define early MR-signal abnormalities in HCC
patients receiving sorafenib monotherapy, which could
be used as potential response criteria to monitor and gov-
ern the new treatment approach of multikinase inhibition
in HCC.
Methods
Demographics
Between September 2005 and May 2008, 21 patients (20
men, 1 woman; age range, 42–77 years; mean, 64.2 years)
with inoperable HCC, no prior systemic treatment, and
Child-Pugh class A or B, received continuous oral soraf-
enib in 4-week cycles (Table 1). Three patients were inves-
tigated in part during the phase III SHARP trial [6]. The
other patients were investigated according to the local
standards for patients at our institution. The institutional
review board approved this retrospective study and
waived informed consent.
Treatment Plan
Patients received sorafenib 800 mg daily (2 × 400 mg
bid), but were allowed up to two dose reductions (400 mg
Table 1: Baseline characteristics with age, gender, histology including tumor differentiation and Child-Pugh score.
Patient Age Gender Histologya Histological differentiationb Child-Pugh
1 58 male HCC + A
2 59 male HCC + A
3 65 male HCC - B
4 72 male HCC ++ A
5 65 male HCC ++ A
6 65 male HCC/CC +/- -c
7 67 male HCC + B
8 63 female HCC ++ A
9 71 male HCC ++ A
10 65 male HCC ++ A
11 43 male HCC ++ A
12 77 male HCC + A
13 54 male HCC + A
14 65 male HCC ++ A
15 66 male HCC + A
16 65 male HCC - A
17 61 male HCC + A
18 76 male HCC - A
19 59 male HCC - B
20 65 male HCC n.d.d A
21 69 male HCC + A
aHCC/CC means a tumor with characteristics of both, hepatic and biliary differentiation.
bHistological differentiation: (++) good, (+) moderate and (-) poor tumor differentiation type.
cNo cirrhosis according to the histology of the liver.
dNo histology available; however, AFP value 1.591 μg/l and typical noninvasive HCC criteria
according to current imaging guidelines.BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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per day or 400 mg every other day/200 mg per day) or a
temporary interruption in case of drug-related toxicities.
Treatment continued until disease progression (PD) or
unacceptable toxicities. Dose delays or modifications
were required for drug-related grade 3/4 toxicities;
patients received lower doses when toxicity improved to
grade 2 or better, but therapy was discontinued if recovery
time was 3 weeks or longer. MR-parameters did not affect
the clinical decision of a further sorafenib treatment.
MR technique
MR-investigations were performed at baseline (pre-treat-
ment) and follow-up (first MRI after a median of 3 weeks
(range, 2–5 weeks); second MRI after a median of an addi-
tional 5 weeks (range, 3–9 weeks); subsequent MR-studies
were performed every 8 weeks (range, 6–8 weeks). Over-
all, a total of 48 MR-investigations were performed and
evaluated.
All patients received baseline MR-scans of the liver; in
patients with metastases additional MR-scans of the chest
or pelvis were performed. All scans were performed using
the same 1.5 T whole-body unit (Magnetom Avanto/
Espree, Siemens Medical Solutions, Erlangen, Germany).
The body coil was used for radiofrequency transmission
and the flexible matrix body coil in combination with the
spine matrix was used for signal detection. For the Gd-
enhanced MR-imaging, gadopentetate dimeglumine
(Magnevist; Bayer Vital GmbH, Leverkusen, Germany)
was administered as an intravenous bolus injection (0.1
mmol/kg) at 2 ml/s followed by a saline flush and image
acquisition 2 min later.
The MR-protocol included axial T1-weighted images
(T1WI), T2-weighted images (T2WI), Gadolinium (Gd)-
enhanced dynamic sequences (VIBE) and additional post-
contrast imaging. T1WI were acquired before and after
contrast media administration with a standard spoiled
gradient echo sequence (FLASH, 2D encoded). Sequence
parameters: TR 205 ms, TE 4.1 ms, flip angle 70°, band-
width 140 Hz/pixel. Chemical-shift selective fat suppres-
sion was used. Slice thickness 5 mm, FoV 360 × 270 mm2,
matrix size 256 × 134, voxel size 2.0 × 1.4 × 5.0 mm3. A
3D fat-suppressed VIBE sequence was obtained before
and 15, 30, 60 and 120 s after the start of the IV contrast
administration. Due to the slightly different number of
slices needed for whole liver coverage depending on the
organ size, the length of each VIBE-sequence was 15–20 s.
Thus, the second VIBE sequence was performed ca. 30–35
s after contrast administration whereas the other two VIBE
sequences were performed 60 and 120 s after the contrast
was IV given. T2WI images were acquired with a fast spin
echo sequence (TR 1250 ms, TE 96 ms, flip angle 150°,
bandwidth 300 Hz/pixel, echo spacing 7.4 ms, fast spin
echo factor 13). Chemical-shift selective fat suppression
was used. Slice thickness 5 mm, FoV 360 × 270 mm2,
matrix size 320 × 180, voxel size 1.5 × 1.1 × 5.0 mm3.
Additional coronal HASTE (TE/TR, 1100/118 ms) images
of the liver were performed. A delayed contrast-enhanced
axial fat-suppressed FLASH sequence was performed 2
min after the dynamic study (ca. 5 min after the start of
the IV contrast administration).
Response Assessment by Size and Volume Measurements
For the decision whether sorafenib therapy was continued
or stopped due to progression under treatment, response
was assessed for every MR-scan based on investigator-
assessed one-dimensional tumor size  measurements
according to modified RECIST criteria [10]. In case of a
confluence of several tumor lesions the joint diameter was
considered for further measurements. Only one patient
(#15) presented with ill-defined extra-hepatic osseous
HCC-manifestations that could not reliably be measured
at follow-up. To verify investigator observations in an
unbiased manner, an independent assessment of the MR
scans was performed retrospectively for all patients.
Additionally, entire tumor volumes and the volume of subse-
quent necrosis within the tumors were calculated by
three-dimensional measurements (in cm3). Next, the ratio
of the necrosis volume [NV] in relation to the entire
tumor volume [TV] was calculated (percentage of [NT]/
[TV]) and expressed as a score: <25%, <50%, <75%, or
>75 (Table 2). Occurrence or progression of a central or
diffuse decrease or absence of Gd-enhancement with sub-
sequent signal hypointensity was considered typical for
tumor necrosis.
Response Assessment by Tumor Signal Changes
The investigation of the sorafenib treated patients was not
simply based on tumor size measurements but included
additional MRI parameters: the assessment of signal
abnormalities occurring in the tumor on T1WI and T2WI
as well as on post-gadolinium images. These parameters
were employed to monitor the development of hemor-
rhagic necrosis, thus providing an insight into the mor-
phologic and functional intratumoral changes under
therapy. Lesions that underwent previous local therapy
(RFA, TACE, etc.) were excluded from the analysis. Lesions
with a diameter of <1 cm, that remained stable during the
study and were not histologically proven to be malignant,
were not evaluated because of the limited ability of MRI
to reliably resolve small structures. For image interpreta-
tion, signal characteristics on T1WI and T2WI were com-
pared to the signal of adjacent normal liver by visual
assessment according to an established grading described
by van den Bos et al. [16]: 1 = markedly hypointense; 2 =
slightly hypointense; 3 = isointense; 4 = slightly hyperin-
tense; 5 = markedly hyperintense. The gold standard forBMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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Table 2: MRI signal and tumor characteristics of HCC target lesions at baseline and follow-up
Pat. Dose
(mg)#
MRI-FU Lesion
(no.)
Size
(mm)
T1 T2 fs Necr. [NT]/[TV] (%) Sum
(mm)
1 - baseline liver 25 2 4 - - 25
800 3 w. (1) 30 4 4 ↑ <25 30
800 8 w. 30 2 5 ↑ <25 30
800 16 w. 34 2 5 ↑ <25 34
2 - baseline liver 160 2 3 + <50 170
400 2 w. (2) 165 4 5 ↑ <50 175
800 6 w. 160 4 3 ↑ <75 172
400 14 w. 155 2 3 ↑ >75 172
3 - baseline liver 35 2 4 - - 35
800 2 w. (4) 35 2 4 - - 35
200 6 w. 35 2 4 - - 35
200 12 w. 39 4 3 ↑ <25 39
4 - baseline liver 57 3 4 + <25 57
800 4 w. (1) 57 4 5 ↔ <25 57
5 - baseline liver 30 2 4 + <25 30
800 2 w. (1) 30 2 4 ↔ <25 30
800 6 w. 31 2 5 ↔ <25 31
400 13 w. 30 2 5 ↔ <25 30
400 20 w. 40 2 5 ↔ <25 40
6 - baseline liver 133 2 4 + <25 133
800 3 w. (1) 135 3 5 ↑ <25 135
800 7 w. 130 2 3 ↔ <25 130
7 - baseline liver 38 2 2 + <25 70
800 2 w. (3) 45 5 4 ↑ >75 80
-8  w . 3 2 3 3 ↓ <50 66
400 16 w. 32 3 3 ↓ <25 71
8 - baseline adrenal 45 3 3 + <25 144
800 3 w. (3) 45 5 4 ↑ <25 144
400 8 w. 57 5 4 ↑ <25 156
9 - baseline liver 20 2 4 - - 119
800 5 w. (3) 22 4 5 ↑ >75 123
800 14 w. 20 4 5 ↑ >75 119
800 20 w. 20 2 4 ↑ >75 119
10 - baseline perit. 12 2 3 - - 12
800 2 w. (2) 12 3 5 ↑ +* 12
800 7 w. 6 3 3 ↔ +* 6
400 15 w. 0 - - - - 0
400 23 w. 0 - - - - 0
11 - baseline liver 10 2 4 - - 19
800 3 w. (2) 14 2 4 - - 26
800 7 w. 17 2 4 - - 31
800 15 w. 18 2 4 - - 35
800 22 w. 21 2 4 - - 38BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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12 - baseline adrenal 15 2 4 + <25 50
800 4 w. (2) 12 2 4 ↑ <50 42
800 12 w. 8 2 5 ↑ <50 36
200 19 w. 8 2 5 ↔ <50 38
13 - baseline liver 38 3 4 + <25 38
400 3 w. (1) 38 3 3 ↑ <25 38
-7  w . 5 5 4 3 ↑ <25 55
200 15 w. 39 3 3 ↑ <50 39
14 - baseline liver 17 5 2 + <25 70
800 2 w. (2) 17 5 2 ↔ <25 70
800 5 w. 17 5 2 ↑ <50 70
200 15 w. 17 5 2 ↔ <50 70
400 23 w. 17 5 2 ↑ >75 70
15 - baseline bone 45 4 2 - - 149
800 5 w. (3) 55 5 4 ↑ >75 176
800 9 w. 45 4 5 ↔ >75 193
800 16 w. 44 4 4 ↔ >75 172
800 21 w. 45 5 4 ↔ >75 168
800 24 w. 50 5 3 ↔ >75 163
800 32 w. 60 4 3 ↔ >75 172
16 - baseline liver 52 4 2 + <25 83
400 3 w. (2) 52 4 2 ↔ <25 83
-9  w . 5 2 3 2 ↔ <25 83
17 - baseline liver 51 1 4 + <25 93
800 4 w. (2) 57 4 5 ↑ >75 107
18 - baseline liver 120 1 4 + <50 120
800 7 w. (1) 130 1 4 ↓ <50 130
19 - baseline liver 151 1 4 + <25 201
400 6 w. (2) 155 4 2 ↑ <50 210
800 18 w. 165 5 5 ↑ >75 229
20 - baseline liver 15 3 3 - - 15
400 2 w. (1) 15 5 4 ↑ <50 15
21 - baseline liver 62 2 4 - - 88
400 8 w. (2) 75 4 5 ↑ <50 97
200 15 w. 75 4 5 ↔ <50 97
200 22 w. 81 3 3 ↔ <50 96
200 29 w. 98 5 5 ↓ <50 113
Abbreviations:
Pat.: patient number. #Daily dose at the time point of each MRI imaging study. MRI-FU: MRI at follow-up;
w.: week after therapy initiation. Lesion: location of representative analysed lesion and number of total lesions at this location. Size: size of the 
representative tumor lesion im mm. T1: T1-weighted image. T2fs: T2-weighted fat saturated image. Qualitative assessment of signal in relation to 
the signal of liver parenchyma (1 = markedly hypointense; 2 = slightly hypointense; 3 = isointense; 4 = slightly hyperintense; 5 = markedly 
hyperintense).
PV: portal vein; perit.: peritoneal. Gd: Gadolinium-enhancement at baseline and its evolution at follow-up
(↑ = increase; ↓ = decrease; ↔ = unchanged; (-) no necrosis detectable; (+) necrosis at baseline detectable). [NT]/[TV]% = percentage of necrosis 
volume to total tumor volume, expressed as a score with (--) no necrosis, <25%, <50%, <75%, or >75%. Sum (mm) = sum of the diameter of all 
detectable lesions at this location.
+* = the necrotic areas could not be reliably quantified.
Table 2: MRI signal and tumor characteristics of HCC target lesions at baseline and follow-up (Continued)BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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assessment of response to sorafenib monotherapy was the
joint clinical and MRI follow-up, according to RECIST.
Statistical Methods
Tumor lesions were classified for presence or absence of
increased T1 signal, tumor necrosis and increase in
necrotic volume to the entire tumor volume [NV/TV].
Fisher's exact tests were used to assess the association
between categorical variables, whereas p < 0.05 was
regarded a significant relationship between the classifica-
tion factors.
Results
Patients' baseline characteristics with respect to age, sex,
and tumor histology including differentiation and Child-
Pugh score are shown in Table 1. Information to sorafenib
doses at follow-up is included in Table 2.
Response Assessment by Measurement of Size and Volume
In 38% of our patients, tumor lesions experiencing mor-
phological signs compatible with tumor necrosis under
sorafenib showed at least a temporary increase in tumor
size, up to 58% of the initial size of the lesion, suggesting
that this might reflect an increased volume of liquid
tumor parts. In 3 patients volume increase of HCC was
found to be over the 20% threshold stipulated by RECIST,
in 3 other patients volume increase was >10% of the ini-
tial lesion's volume (Table 2). In 3 patients (#1, #13, and
#15) a substantial reduction of the whole tumor volume
could be achieved under sorafenib (reduction of 36%,
45%, and 30%, respectively). Of note, two patients (#7,
#21) undergoing long- and short-term sorafenib dose
interruptions experienced repeated responses with tempo-
ral variations in tumor volume.
Response Assessment by Measurement of Tumor Necrosis
On post-gadolinium fat-saturated T1WI, areas of tumor
necrosis appeared de novo in 7/21 patients (Table 2) and
13/39 lesions (data not shown) or increased in 9/21
patients (Table 2) and 9/39 lesions (data not shown). In
patients with progressive necrosis 2 lesions developed
<25% necrosis, 4 lesions achieved <50% necrosis, and 7
lesions developed >75% tumor necrosis at follow-up.
Altogether, progression of necrosis (↑) was diagnosed in
40/117 followed-up lesions (data not shown). Notably,
reduction (↓) of the volume of tumor necrosis was regis-
tered only in 3 patients (#7, #18, and #21). The former
two had progressive disease at follow-up with revitaliza-
tion of tumor. The latter presented an undulant course of
the disease due to intermittent dose discontinuations.
Assessment of T1WI and T2WI signal changes as a 
surrogate marker for intratumoral hemorrhage
A focal or diffuse increase in tumor signal to baseline, con-
firmed independently by both readers, was detected on
nonenhanced T1WI in 15/21 patients (Table 2) and 28/39
target lesions analysed (data not shown) at an early time
point after a median of 5 weeks (range, 2–9 weeks) fol-
lowing onset of sorafenib therapy, and considered suspi-
cious of hemorrhage and/or protein-rich necrosis.
Interestingly, one patient with a complete response (#10)
displayed early signal changes in T1WI, T2WI and an
increase of necrotic areas within the tumor already 2
weeks after initiation of sorafenib therapy 400 mg bid.
Increased signal on T1WI returned to normal with time,
but the dynamics of this phenomenon could not be
entirely analysed due to different time spans of the
patients' individual MR-surveys. In five patients (#5, #11,
#12, #14, #18), the T1WI tumor signal remained
unchanged during follow-up. However, two of them
developed an increase of the T2-signal (#5, #12) while in
two patients a substantial progression of the necrotic
tumor area could be detected (#12, #14) at time.
A synchronous signal increase on T2WI SE-sequences or
rarely a temporary signal decrease was considered as fur-
ther supporting the hypothesis of tumor hemorrhage.
Almost synchronously with early signal intensity changes
on T1WI, signal abnormalities on T2WI were found
(median, 5.3 weeks; range, 2–12 weeks), consisting in
most of the cases (15/21 patients) of an increase in signal
intensity (Table 2) and in 26/39 target lesions analysed
(data not shown), whereas a decrease in T2-signal lesions
was found in only 2/21 patients. In two patients (#5, #12)
with stable signal patterns on T1WI, signal changes could
be assessed only on T2WI. Thus, early signal abnormali-
ties suggestive of tumor hemorrhage occurring after onset
of sorafenib therapy were encountered in 15/21 patients.
Typical examples of signal intensity changes of MRI base-
line imaging and follow-up investigations are presented
in Figure 1, 2 and 3 for three representative patients
(patients #7, #8, and #17). In Figure 1, typical changes
from a patient presenting with a T1WI hypointense tumor
signal at baseline and consecutive changes under therapy
are shown. Figure 2 demonstrates synchronous hemor-
rhagic necrosis in all hepatic lesions of a patient with mul-
ticentric HCC 3 weeks after onset of sorafenib therapy.
Figure 3 demonstrates increased signals on T1WI and
T2WI occurring synchronously in all HCC manifestations
after onset of sorafenib therapy. Of note, one patient
(#21) presented a slow but continuous growth of the
hepatic lesions despite typical signal changes on T1WI
and T2WI. This patient had repeated therapy interruptions
and a dose reduction due to a hand-foot syndrome, but a
repeated increase in T1WI was observed following the re-
onset of sorafenib. Two patients in this series, who
showed a continuous tumor growth under treatment
(#11, #18), showed no sorafenib related signal abnormal-BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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ities on MRI at all and no de novo occurring or progressive
necrosis.
Potential Influence of Sorafenib Dose on Tumor Signal
Thus, early changes occurred in the 8 patients that were
able to take sorafenib 800 mg daily within a mean auf 4.1
weeks (range, 3–5). Taking all 18 patients together who
received either sorafenib 800 mg or 400 mg daily, the lat-
ter being the first dose reduction level, early changes could
be detected within a mean of 4.2 weeks (range, 2–9),
demonstrating that both dose levels had a similar reaction
pattern. However, in a further patient who had to reduce
sorafenib to 200 mg due to adverse reactions early in the
therapy course, MRI signal alterations and new tumor
necrosis could be detected at week 12 under therapy. Of
note, the 2 patients with a longer duration until a signal
response could be detected (#3, #16) had to temporarily
discontinue therapy within the first two weeks due to a
grade 3 skin reaction or a transient increase in bilirubin
levels, respectively.
In conclusion, we show for the first time that rapid
changes in MR signal intensities occur soon after onset of
sorafenib therapy. A statistical analysis addressing the
presence or absence of an increased T1WI signal, tumor
necrosis, and increase in the necrotic volume in relation to
the entire tumor volume [NV/TV] showed a significant
relationship between T1WI and tumor necrosis (p =
0.017) and between tumor necrosis and NV/TV (p =
0.002). The direct association between T1WI and NV/TV
did not reach statistical significance (p = 0.129) in this
small sample size
A-F. 63-year-old female patient with multicentric HCC (patient #8) Figure 1
A-F. 63-year-old female patient with multicentric HCC (patient #8). Axial nonenhanced T1WI performed at baseline 
showed a 10 cm large tumor (arrow) in the left liver lobe (Figure 1A). Note a tumor signal (arrow) slightly hypointense to nor-
mal liver parenchyma with a small ventral heterogeneous hyperintense area caused by earlier radiofrequency (RFA) ablation. 
On baseline T2WI, the tumor revealed diffuse mild hyperintensity and a small hypointense area corresponding to the ablation 
site (Figure 1B). Baseline fat-suppressed post-gadolinium (Gd) imaging demonstrated diffuse tumor enhancement (arrows) with 
focal necrosis due to the earlier RFA procedure (arrowhead) (Figure 1C). Three weeks after onset of sorafenib, T1WI imaging 
detected multiple focal hyperintense lesions (arrows) in part with sedimentation levels that have occurred during therapy (Fig-
ure 1D). On T2WI at the same time, corresponding hyperintense lesions were seen (arrows) (Figure 1E). Fat-suppressed post-
Gd imaging revealed extensive necrosis (arrows) and reduction in tumor perfusion (Figure 1F).BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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Discussion
Targeted therapy refers to a new generation of anticancer
drugs, designed to interfere with distinct molecular enti-
ties, involved in tumor growth and/or progression. The
multikinase inhibitor sorafenib demonstrated profound
anti-tumor activity in different clinical settings, including
HCC [5,6,17], renal cell carcinoma (RCC) [9,18], as well
as other advanced, so far therapy-refractory tumor entities
[19,20]. In the special situation of HCC, imaging studies
have to take into account that tumor areas develop within
a heavily diseased liver, in which several clonal tumor
areas with different patterns of differentiation might exist
simultaneously [2,3].
In our patient population a substantial impact of soraf-
enib on the MRI pattern of HCC tissues was observed,
which might be regarded at least as some kind of a therapy
response; however, the majority of these changes did not
lead to a classification of a partial response according to
classical RECIST criteria. Nevertheless, 16 out of 21
patients presented with either new or progressive necrosis
in repeated MRI scans, which suggests that quantifying
necrotic areas in relation to the entire tumor volume
might be useful as a reliable predictive marker of therapy
response. Similar results have been described for 11 HCC
patients under sorafenib treatment using a semiauto-
mated computerized technique to analyse tumor necrosis
in contrast enhanced CT scans [5]. However, the influence
of tumor necrosis on the clinical outcome, including over-
all survival data, has not been prospectively investigated
yet.
Reaction patterns to targeted agents like sorafenib seem to
foremost include (i) disease stabilization (rather than a
A-F. 71-year-old male patient with multifocal HCC (patient #9) Figure 2
A-F. 71-year-old male patient with multifocal HCC (patient #9). Axial nonenhanced fat-suppressed T1WI imaging of 
the liver performed at baseline showed multiple mild hypointense HCC lesions (arrow) (Figure 2A). On corresponding coronal 
HASTE (T2-weighted) images, liver tumors are difficult to distinguish from adjacent liver parenchyma because of signal isoin-
tensity (Figure 2B). Fat-suppressed post-Gd SGE imaging showed an almost homogenous signal (arrows) of moderately enhanc-
ing liver tumors (Figure 2C). Three weeks after onset of sorafenib therapy, nonenhanced T1WI imaging revealed multiple focal 
strongly hyperintense lesions (arrows) presumed to represent hemorrhagic necrosis in the known tumors (Figure 2D). Coro-
nal HASTE images performed at the same time demonstrated also hyperintense signals (arrows) of tumors with a good deline-
ation to adjacent liver parenchyma (Figure 2E). Fat-suppressed post-Gd SGE imaging showed central >75% necrosis in most of 
the HCC lesions following sorafenib therapy (Figure 2F).BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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direct cytotoxic effect accompanied by tumor shrinkage)
or (ii) an induction of intralesional necrosis that does not
automatically lead to a marked decrease in tumor size. In
this context, a surprising finding of our study was that
more than one third of the tumors that displayed new
necrotic areas under treatment showed a temporary
expansion, which seemed to be primarily due to an
increased volume induced by tumor necrosis and not by
an accumulation of vital tumor cells. Interestingly, com-
parable data have been reported in patients with gastroin-
testinal stromal tumors (GIST), a different tissue context
receiving therapy with the tyrosine kinase inhibitor imat-
inib mesylate (STI571; Gleevec™) [21]. This information
must be taken into account when judging tumor
responses under treatment with both, single kinase (e.g.
imatinib mesylate) as well as multikinase inhibitors (e.g.
sorafenib).
Especially in the context of HCC, MRI provides a highly
sensitive method for detecting soft tissue signal changes,
to assess the extent of therapy-related tumor necrosis, and
to monitor both, distinct hepatoma nodules as well as the
surrounding liver parenchyma in exquisite detail [22]. It is
obvious that signal abnormalities related to sorafenib that
occur at a distinct time point are only temporary in nature
because of a continuous alteration of therapy induced sig-
nal abnormalities, e.g. by physiologic processes, leading
to hemoglobin degradation or change in the tissue pro-
tein content. Both protein-rich secretion due to rapid
tumor necrosis or hemorrhage could explain signal abnor-
malities on MRI. However, taken all signal abnormalities
occurring on T1WI and T2WI and their temporary evolu-
tion into account, hemorrhage seems to be much more
plausible. Theoretically, looking at an early time point
soon after the initiation of a targeted therapy, the appear-
ance of intracellular deoxyhemoglobin is expected to
A-F. 61-year-old male patient with metastatic HCC (patient #17) Figure 3
A-F. 61-year-old male patient with metastatic HCC (patient #17). Axial nonenhanced T1WI imaging of the liver 
showed hypointense signal of all HCC lesions (arrows) (Figure 3A). On corresponding T2WI images, HCC lesions demon-
strated all a moderate hyperintense signal (arrows) compared to adjacent liver parenchyma (Figure 3B). Fat-suppressed post-
Gd SGE imaging revealed a diffuse enhancement throughout all HCC lesions (arrows) with small central areas of necrosis 
(arrowhead) (Figure 3C). Five weeks after onset of sorafenib therapy, the signal of HCC lesions on T1WI- imaging increased 
(arrows) becoming iso- to hyperintense to adjacent liver parenchyma (Figure 3D). At this time, there was at best mild increase 
in tumor signal on fat-suppressed T2WI imaging (arrows) (Figure 3E). However, fat-suppressed post-Gd T1WI demonstrated 
>75% reduction of enhancing tumor areas due to necrosis (arrows) (Figure 3F).BMC Cancer 2009, 9:208 http://www.biomedcentral.com/1471-2407/9/208
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induce low signal intensities on both T1WI and T2WI,
similar to well-known signal abnormalities, occurring
early in acute hemorrhage due to other causes (days 1 – 3
after occurrence). However, detection of such changes is
expected to be less sensitive in tumors that present ini-
tially with either isointense signals or signal intensities
that are only slightly different from that of adjacent liver
parenchyma and would require a very early monitoring,
for instance by MR-imaging, which was not the focus of
our study. In the subsequent early subacute phase (> 3
days after onset of hemorrhage), the transformation of
intracellular deoxyhemoglobin to methemoglobin is
known to induce a change of the MR-signal to high inten-
sities on T1WI and low intensities on T2WI images,
whereas in the late subacute phase (> 7 days post hemor-
rhage), the occurrence of extracellular methemoglobin
results in high signals in both T1WI and T2WI, which con-
trasts much better with the native tumor and liver paren-
chymal signal. This time span (first weeks after initiation
of therapy) seems to be most adequate for accurate dem-
onstration of hemorrhage in tumors as caused by soraf-
enib and corresponds to our imaging schedule. Other
theoretical causes for an increase of signal intensity on
nonenhanced T1WI include a protein-rich necrosis, simi-
lar to a coagulation necrosis that occurs after radiofre-
quency ablation. However, in that setting, the T2WI signal
of those lesions is expected to be low and persists for a
much longer time period than hemorrhagic alterations
observed in our sorafenib treated patients. Nevertheless,
the exact time required for the reconversion of MR signals
to baseline values could not be reliably determined, as the
influence of variable sorafenib dosages remains
unknown.
Alternative explanations for signal abnormalities occur-
ring during sorafenib treatment in our cohort include
tumor hemorrhage or necrosis induced by tumor progres-
sion. However, the latter could indirectly be excluded by
further follow-up MR imaging studies, which demon-
strated either tumor size stabilization or more often a con-
tinuously rising ratio of the volume of necrotic tumor
areas to viable tumor tissue.
There are some limitations of our work, first of all caused
by the small number of patients recruited and evaluated.
Follow-up studies with larger numbers of patients are
needed in order to validate our results and establish the
accuracy of such a response assessment. Secondly, for sci-
entific reasons it would be desirable to compare radiolog-
ical signal changes under therapy with histological
alterations. However, due to ethical considerations, such
a parallel evaluation is not feasible in humans. Neverthe-
less, long-term monitoring as in our study is regarded as
an acceptable alternative.
Conclusion
In summary, early changes within T1WI, T2WI, Gd-
enhancement and necrotic tumor areas seem to define
rapid therapy responses in HCC patients receiving soraf-
enib. Due to the observation that an induction of intrale-
sional necrosis does not automatically correlate with a
decrease in tumor size, the application of classical RECIST
criteria may not be suitable to identify patients who ben-
efit from the sorafenib therapy. Therefore, the prospective
value of early MRI changes within one or several of the
investigated parameters and a predefined time frame, with
respect e.g. to a survival benefit should be evaluated pro-
spectively in subsequent larger clinical trials. Prognostic
parameters being available within weeks of therapy initia-
tion could be beneficial in two ways: (i) MR-imaging
could lead to an early change of the therapeutic strategy
and thus influence the outcome in these HCC patients;
(ii) severe side effects as well as a substantial amount of
costs potentially could be avoided in well-defined non-
responders.
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